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Abstract
Current control strategies for soil-transmitted helminths (STH) emphasize morbidity control
through mass drug administration (MDA) targeting preschool- and school-age children,
women of childbearing age and adults in certain high-risk occupations such as agricultural
laborers or miners. This strategy is effective at reducing morbidity in those treated but, with-
out massive economic development, it is unlikely it will interrupt transmission. MDA will
therefore need to continue indefinitely to maintain benefit. Mathematical models suggest
that transmission interruption may be achievable through MDA alone, provided that all age
groups are targeted with high coverage. The DeWorm3 Project will test the feasibility of
interrupting STH transmission using biannual MDA targeting all age groups. Study sites
(population80,000) have been identified in Benin, Malawi and India. Each site will be
divided into 40 clusters, to be randomized 1:1 to three years of twice-annual community-
wide MDA or standard-of-care MDA, typically annual school-based deworming. Commu-
nity-wide MDA will be delivered door-to-door, while standard-of-care MDA will be delivered
according to national guidelines. The primary outcome is transmission interruption of the
STH species present at each site, defined as weighted cluster-level prevalence2% by
quantitative polymerase chain reaction (qPCR), 24 months after the final round of MDA.
Secondary outcomes include the endline prevalence of STH, overall and by species, and
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the endline prevalence of STH among children under five as an indicator of incident infec-
tions. Secondary analyses will identify cluster-level factors associated with transmission
interruption. Prevalence will be assessed using qPCR of stool samples collected from a ran-
dom sample of cluster residents at baseline, six months after the final round of MDA and 24
months post-MDA. A smaller number of individuals in each cluster will be followed with
annual sampling to monitor trends in prevalence and reinfection throughout the trial.
Trial registration
ClinicalTrials.gov NCT03014167
Author summary
Soil-transmitted helminths (STH) affect 1.45 billion people worldwide, and high intensity
infections are associated with anemia, undernutrition and impaired cognition, particu-
larly among children. Mathematical models suggest it may be possible to interrupt the
transmission of STH in a community by expanding mass drug administration (MDA)
from targeted high-risk groups (primarily school-aged children and women of child-bear-
ing age) to all community members with high coverage. The DeWorm3 Project will test
the feasibility of this approach to interrupting the transmission of STH using a series of
cluster randomized trials in Benin, India and Malawi. Each study area (population
80,000) will be divided into 40 clusters and randomized to community-wide or stan-
dard-of-care targeted MDA for three years. Two years following the final round of MDA,
prevalence of STH will be compared between arms and transmission interruption assessed
in each cluster. The DeWorm3 trials will provide stakeholders with information regarding
the potential to switch from STH control to a more ambitious and sustainable strategy.
Introduction
The soil-transmitted helminths (STH) are group of intestinal parasites (Ascaris lumbricoides,
Ancylostoma duodenale, Necator americanus and Trichuris trichiura) targeted for control by
the London Declaration. These parasites infect an estimated 1.45 billion people globally, result-
ing in the loss of almost 5 million disability adjusted life years (DALYs) annually [1, 2]. High
to moderate intensity STH infections are associated with increased risk of malnutrition, iron-
deficiency anemia and other adverse physical and cognitive morbidities, particularly in chil-
dren. The current World Health Organization (WHO) strategy for controlling STH is based
on mass drug administration (MDA) of albendazole or mebendazole to pre-school and
school-age children (PSAC and SAC), women of childbearing age (including pregnant women
in the second and third trimesters and breastfeeding women) and adults in certain high-risk
occupations such as agricultural laborers or miners, with the goal of eliminating STH-related
morbidity [3–5].
While the current strategy of MDA for STH control has proven successful in controlling
morbidity, the incidence of reinfection post-treatment is high and targeted MDA is unlikely to
break transmission of STH in many settings[6]. This is in large part due to adult reservoirs of
disease [7, 8]. Even if coverage of all targeted populations were optimized, the current STH
strategy would likely need to be continued until significant economic development and
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universal water, sanitation and hygiene (WASH) access are able to interrupt transmission[9].
As a result, there is increased interest in alternative strategies to interrupt STH transmission
using broadly administered MDA strategies targeting all age groups [10], which a recent sys-
tematic review and meta-analysis showed are more effective in reducing the prevalence of
STH infection[11]. Several trials investigating the differential impact of community-wide ver-
sus school-based MDA on STH transmission are currently underway.[12, 13]
Other NTD programs have been successful in achieving high treatment coverage of MDA
to entire communities, including adults. For example, programs targeting lymphatic filariasis
(LF) elimination have achieved considerable community acceptability and high MDA cover-
age in many endemic countries. Of the 73 countries endemic for LF in 2014, 18 have discon-
tinued MDA and are in a state of post-MDA surveillance, pending confirmation that LF
transmission has been interrupted [14]. Given that LF programs provide five to seven rounds
of MDA to entire communities with albendazole (in combination with ivermectin or diethyl-
carbamazine), there is a unique opportunity to leverage the LF program platform to continue
community-wide MDA after programs have proceeded to surveillance and attempt to break
the transmission of STH.
The DeWorm3 Project (ClinicalTrials.gov Identifier NCT03014167) will conduct a series of
community cluster randomized trials in India, Malawi and Benin in order to determine
whether continuing community-wide MDA with albendazole following cessation of LF pro-
grams can interrupt the transmission of STH (Ascaris lumbricoides, Ancylostoma duodenale,
Necator americanus and Trichuris trichiura) in focal geographic areas. Specifically, this project
will demonstrate the feasibility of interrupting STH transmission using a strategy of twice-
annual community-wide MDA, compared to the current national STH strategy at each site.
Aims and objectives
The general objective of DeWorm3 is to determine the feasibility of interrupting the transmis-
sion of STH (A. lumbricoides, A. duodenale, N. americanus and T. trichiura) in focal geographic
areas in Africa and Asia by expanding the population targeted and the frequency of delivery of
MDA with albendazole.
To address this objective, in trial sites in India, Malawi and Benin, where LF programs have
delivered at least five rounds of MDA of albendazole (plus ivermectin or DEC), clusters will be
randomized to receive twice-annual community-wide MDA or standard of care (current
national STH MDA strategy, Table 1) for three years.
Primary objectives:
1. To compare the prevalence of each STH species (A. lumbricoides, A. duodenale, N. ameri-
canus and T. trichiura) measured by quantitative PCR 24 months after stopping MDA,
between clusters randomised to receive twice-yearly community-wide MDA versus clusters
randomised to receive standard of care pre-SAC and SAC targeted MDA.
2. To determine whether the transmission of each STH species (A. lumbricoides, A. duodenale,
N. americanus and T. trichiura) can be interrupted using MDA with albendazole, defined as
reaching a weighted point prevalence of2% of that species measured by quantitative PCR
24 months after stopping MDA in clusters receiving either twice-yearly community-wide
MDA or standard of care pre-SAC and SAC targeted MDA.
Secondary objectives include:
3. To compare the prevalence of each STH species by quantitative PCR in children under 5
years of age by randomization arm 24 months following the last round of MDA.
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Trial summary
The DeWorm3 field trials are a series of community cluster randomized trials conducted in
focal geographic areas in Benin, India and Malawi (Fig 1) comparing twice-annual commu-
nity-wide MDA to the current standard of care MDA (typically school-based deworming) for
interruption of STH transmission. The study is summarized in Table 2. Each study site
includes a minimum total population of 80,000 individuals, to be divided into 40 total clusters
with a minimum population of 1,650 individuals in each. Clusters may consist of one or more
Table 1. DeWorm3 study sites and national mass drug administration (MDA) strategies for control of soil-transmitted helminths (STH) in each
country. Each country’s national guidelines will be followed in the standard of care / control arm of the trial.
Study
site
National Standard of Care STH
Control Strategy
STH endemicity1 Study area
Benin School-based MDA
Targets SAC (5–14 years old)
Modeled 2010 national prevalence[2]:
Hookworm 1–10%
Ascaris 1–10%
Trichuris 1–10%
Commune of Come´, Department of Mono.
Consists of Come´ town and surrounding rural area.
India School-based MDA and National
Deworming Days
Targets PSAC and SAC (1–19 years
old)
Observed 2013–2014 prevalence in
Jawadhu Hills [28]:
Hookworm 18.5%
Ascaris 0.4%
Trichuris <1%
Thimiri and Jawadhu Hills, State of Tamil Nadu.
Largely rural; consists of tribal area in Jawadhu Hills and
additional plains area in Thimiri.
Malawi School-based MDA and Child Health
Days
Targets PSAC and SAC (1–14 years
old)
Modeled 2010 national prevalence[2]:
Hookworm 1–10%
Ascaris 1–10%
Trichuris 1–10%
Mangochi District, Southern Region.
Largely rural; a subset of the district (full population 1 million)
will be included.
1Published estimates available at the time of protocol development; up-to-date baseline prevalences at each site will be measured prior to randomization.
https://doi.org/10.1371/journal.pntd.0006166.t001
Fig 1. DeWorm3 trial sites and partners. Figure created for DeWorm3 using shapefiles from GADM database of Global Administrative Areas 2012,
version 2.0 (gadm.org) and ArcGIS Desktop: Release 10 (Redlands, CA).
https://doi.org/10.1371/journal.pntd.0006166.g001
Interrupting the transmission of STH through MDA: The DeWorm3 trial protocol
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006166 January 18, 2018 4 / 16
villages, settlements or zones within urban areas, and cluster boundaries will take into account
administrative and / or geographic barriers. Clusters will be randomized 1:1 to three consecu-
tive years of either;
1. Twice-annual community-wide MDA (intervention arm), or
2. Targeted MDA (control, standard-of-care arm) delivered in accordance with WHO recom-
mendations and national Ministry of Health (MOH) guidelines.
Randomization of clusters to community-wide vs. targeted MDA will be stratified by site,
and restricted randomization will be performed to ensure balance in baseline factors between
arms; these may include population, age distribution, socio-economic status (SES), WASH
access and urban / rural designation of clusters. Baseline prevalence may be included in the
restricted randomization, depending on the degree of variability between clusters. A list of
restricted randomization scenarios will be generated by the DeWorm3 Clinical Trial and
Implementation Science Support Unit, with the final scenario randomly selected by each site
team.
Primary outcome. Transmission interruption is defined as a cluster-level point preva-
lence2% of the dominant STH species (primary outcome) and any detectable STH species
(secondary outcome) at the study endpoint, measured by qPCR 24 months after the final
round of MDA. The prevalence threshold and post-treatment interval were selected based on
STH transmission models to maximize positive predictive value (PPV), defined here as the
proportion of communities below the threshold in which STH prevalence will progress to
elimination rather than revert to pre-MDA levels after drug pressure is removed. In mathe-
matical models, the PPV of different transmission thresholds varies by STH species and pre-
MDA transmission intensity / starting prevalence, the size of the community, and the post-
Table 2. Summary of the DeWorm3 field trials.
Study Design: Community cluster randomized controlled trial
Intervention: Twice-annual community-wide MDA of albendazole for 3 years delivered to all
individuals over 24 months of age
Control: Targeted MDA of PSAC and SAC with albendazole for 3 years delivered in
accordance with national MOH guidelines
Primary Outcome: Transmission interruption of STH species (weighted prevalence2% 24
months following the final round of MDA)
MDA eligibility criteria: A PSAC or SAC residing in a control cluster OR any resident in an intervention
cluster
Eligible for treatment with albendazole according to WHO and national
guidelines
MDA exclusion criteria: Children under one or two years of age, depending on national guidelines
Women in the first trimester of pregnancy
History of adverse reaction to benzimidazoles
Acutely ill at the time of MDA
Sampling eligibility
criteria:
Residents of the study cluster based on census and questionnaire responses
Provide consent and/or assent (as applicable)
Sampling exclusion
criteria:
Individuals who do not reside in the study cluster
Refusal to consent/assent
Enrollees in the longitudinal monitoring cohort ineligible for inclusion in cross-
sectional sampling
Sampling schedule: Cross-sectional sampling of randomly selected eligible participants will take
place at baseline (pre-MDA), post-treatment (six months following the final
round of MDA), and at endline (24 months following the final round of MDA)
Longitudinal monitoring cohorts will be sampled annually
https://doi.org/10.1371/journal.pntd.0006166.t002
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treatment follow-up interval. An absolute prevalence threshold of 2% at 24 months post-MDA
has a PPV of>0.8 for most scenarios explored in the models, meaning that 80% of communi-
ties that attain the threshold for each individual STH species are expected to progress to elimi-
nation.[15, 16]
Mass drug administration. In the intervention arm, all individuals 24 months of age and
older will be eligible for treatment with albendazole in accordance with WHO guidelines, with
the exception of women in their first trimester of pregnancy, anyone with a history of adverse
reactions to benzimidazoles, and those acutely ill at the time of MDA (Table 2). All eligible
individuals will receive a single dose of albendazole during twice-annual campaigns. House-
to-house MDA will be conducted and study staff or village volunteers will directly observe
MDA compliance; where directly observed treatment is not possible, this will be recorded.
Mop-up campaigns targeting untreated individuals will be conducted in all clusters.
In control clusters, all those targeted by existing national guidelines (primarily PSAC and
SAC) will be eligible for treatment. MDA will be provided through the existing National STH
Program or a similar distribution structure. Eligible individuals will receive a single dose of
albendazole through school-based distribution or during alternative MDA campaigns, accord-
ing to site-specific national guidelines. Non-enrolled SAC and PSAC will be encouraged to
come to school for treatment on deworming days, or will be reached by strategies appropriate
to the local context in collaboration with local ministries and authorities. MDA will be admin-
istered by teachers, health workers or volunteers, according to national practice.
In order to encourage high treatment coverage in the community-wide intervention arm,
enhanced community sensitization activities will take place within one month of scheduled
MDA events. Sensitization activities will be designed in close consultation and collaboration
with the National NTD program and in accordance with site norms and past MDA experi-
ences. Where possible, MDA activities will be scheduled to accommodate seasonal and cultural
activities that might influence MDA participation, such as holidays, migratory events, or crop
harvesting. In the control arm, standard sensitization activities will take place according to
national guidelines.
Data collection
All sites will collect information on a core set of variables with standard definitions. Data col-
lection instruments were developed with input from all sites and will be translated into local
languages. Data will be collected electronically, using Android devices equipped with Sur-
veyCTO software (Dobility, Inc; Cambridge, MA, USA and Ahmedabad, India). Data collected
at each site will be maintained in a harmonized central database with site-specific and central
quality control procedures. Data collection activities are summarized in Fig 2.
Data access. Data collected at each site will be owned by the site’s Project Leads and
National Government and maintained on a site-specific, password-protected SurveyCTO
server. Pooled, de-identified data from all sites will be maintained on a central, password-pro-
tected SurveyCTO server by the DeWorm3 Project. Access to the Project data will be granted
by the Project Leads at each site and the Project PI.
Study area census. An initial baseline census of all individuals residing within the bound-
aries of each study area will be performed, enumerating and collecting basic sociodemographic
information on the inhabitants of each household along with the GPS coordinates of their
dwellings. Up to three attempts will be made to reach each household for inclusion. The base-
line census will provide information on population and STH risk factors to inform initial clus-
ter randomisation. Census updates will then be conducted annually to verify births, deaths,
and migration status of household members. Censuses will enable random sampling of
Interrupting the transmission of STH through MDA: The DeWorm3 trial protocol
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participants for outcome assessment, provide denominator data for MDA coverage assess-
ments, and be used to quantify in- and out-migration. Migration-specific questions on the
census will also be used to determine when mop-up MDA activities will occur in a given
cluster.
Prevalence assessments. Cross-sectional assessments of STH prevalence and intensity
will take place via random sampling from the most recent census. Cross-sectional surveys take
place at baseline (pre-MDA), post-intervention (6 months following the final round of MDA),
and endline (24 months following the final round of MDA). Five hundred people will be sam-
pled per cluster at baseline and post-intervention, while at endline, 1000 people per cluster will
be sampled (Fig 3). Up to three attempts will be made to reach each individual for the purposes
of the cross-sectional prevalence assessments. Cross-sectional assessment data will be used to
inform the study’s primary aims, measuring endline STH prevalence and determining whether
or not transmission interruption has been achieved at a cluster-level. Stool samples will be col-
lected for DNA extraction and qPCR analysis; cycle threshold will be used to assess sample
positivity and as a proxy for intensity of infection. Microscopic examination using Kato-Katz
technique will be performed to assess presence and intensity of infection on a subset of 100
samples per cluster at the post-intervention and endline surveys, while baseline Kato-Katz
assessment will come from the Longitudinal monitoring cohorts (see below).
Longitudinal monitoring cohorts. At baseline, a subset of 150 individuals in each cluster
will be invited to participate in longitudinal monitoring cohorts for the duration of the trial.
The longitudinal cohort will be selected at random from an age-stratified census (30 PSAC, 30
SAC, 90 adults) and participants will be excluded if they report that they plan to move out of
the study area within the study period. These individuals will provide stool samples annually
for immediate analysis using Kato-Katz and whole stool samples will be stored for subsequent
DNA extraction and testing via qPCR. Data collected at interim timepoints in these cohorts
will serve to assess rates of change in STH prevalence, quantify reinfection after a negative test
where applicable, and to validate and refine mathematical models. Individuals who are part of
the longitudinal monitoring cohorts will not be eligible to provide samples for cross-sectional
sampling.
Fig 2. Schematic of planned data and sample collection time points for the DeWorm3 field trials.
https://doi.org/10.1371/journal.pntd.0006166.g002
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Coverage surveys. A random sample of 50 households in each cluster will be invited to
participate in a post-MDA coverage survey within one week of community-wide or standard
of care MDA taking place in that cluster. Coverage surveys will be conducted prior to any clus-
ter-wide mop-up activities in the intervention arm. All individuals in the selected household
will be invited to participate in the coverage survey, regardless of whether they were intended
recipients of MDA. A subsample of those participants surveyed within 72 hours of MDA in
their clusters will be asked to provide a urine sample for coverage validation by detection of
albendazole metabolites. Treatment coverage is defined as the proportion of eligible individu-
als who were reached by MDA activities and who ingested albendazole during MDA; coverage
of the intervention and adherence to treatment will be assessed separately. Questions in the
survey align with WHO-endorsed coverage survey for use by national programs[17]. In accor-
dance with NTD coverage survey guidelines, the individuals who conduct the coverage survey
in a given cluster will not be the same individuals who delivered the drugs [18].
School facility surveys. An annual school facility survey will also be conducted to assess
the presence of water and sanitation facilities at schools in all clusters and to determine the
enrollment and attendance rates of children in the study site. These data provide an opportu-
nity to validate the annual census and to understand the totality of children’s risk for STH
acquisition.
Fig 3. Flow chart showing outcome assessment in the DeWorm3 field trials.
https://doi.org/10.1371/journal.pntd.0006166.g003
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Study management and coordination
Principal Investigators (PIs) at each site are responsible for the conduct of trial procedures,
with central coordination of trial activities by the Project PI and team at the Natural History
Museum in London. The DeWorm3 coordinating team at the Natural History Museum is sup-
ported by five units: (1) the Clinical Trial and Implementation Science Support Unit at the
University of Washington, USA, (2) the Modeling and Trial Simulation Support Unit at Impe-
rial College London, (3) the Economic Analysis Support Unit at Swiss Tropical and Public
Health Institute, (4) the Trial Conduct and Coordination Support Unit, London Applied &
Spatial Epidemiology Research Group (LASER), London School of Hygiene & Tropical Medi-
cine; and (5) the STH Molecular Diagnostics Support Unit at Smith College, USA and the
Christian Medical College, Vellore, India.
A community advisory board (CAB) will be established at each study site and designed in
accordance with site preferences in order to guide and inform appropriate implementation of
all study procedures and engagement with community members.
A four-member Data Safety and Monitoring Committee (DSMC) has been formed to eval-
uate the statistical analysis plan and monitor study progress and severe adverse events (SAEs).
MDA programs distributing albendazole will conduct passive adverse event (AE) monitoring
and reporting. SAEs, including all deaths and any events classified as “definitely”, “probably”
or “possibly” related to the study drug according to WHO criteria, will be reported to the
DSMC and to all appropriate regulatory bodies within 48 hours of the study team becoming
aware of them.
Ethics statement
The DeWorm3 Project has been reviewed and approved by the Institut de Recherche Clinique
au Be´nin (IRCB) through the National Ethics Committee for Health Research (002-2017/
CNERS-MS) from the Ministry of Health in Benin, The London School of Hygiene and Tropi-
cal Medicine (12013), The College of Medicine Research Ethics Committee (P.04/17/2161) in
Malawi and the Christian Medical College Institutional Review Board in Vellore, India
(10392). The study was also approved by The Human Subjects Division at the University of
Washington (STUDY00000180).
Consent procedures. Data collectors will obtain consent / assent as appropriate prior to
all data collection activities. Written informed consent will be sought if the individual can
write, while for any individual who cannot write, oral consent will be given in the presence of a
witness and documented with a thumbprint. The use of oral consent in these circumstances
has been approved by the relevant ethical committees.
The head of household or other adult member of the household will give informed consent
for participation in the baseline census and annual updates. Participants in each round of
cross-sectional sampling and in the coverage survey will give informed consent for their partic-
ipation. Participants in the longitudinal monitoring cohorts will provide consent for repeated
sample collection and repeated rounds of data collection at enrollment. If a child is selected for
any of the above activities, parents or guardians will give informed consent on behalf of the
child; children will provide assent in accordance with national ethical guidelines. Consent for
participation in the school facility survey will be sought from head teachers or others with deci-
sion-making authority on behalf of each school. Approval to approach each school will be
sought from Ministries of Education if required by each country’s guidelines.
Treatment of STH infections identified by Kato-Katz. Following cross-sectional and
longitudinal surveys, all individuals in the intervention arm with STH infections identified
using Kato-Katz will be treated during community-wide MDA. All PSAC and SAC in the
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control arm with identified infections will be treated during targeted MDA. WHO guidelines
do not recommend MDA for adults; however, any adult (15 years of age) in control clusters
found by Kato-Katz a) to have moderate to heavy intensity STH infection according to WHO
definitions[19] or b) to require treatment according to each country’s guidelines will be pro-
vided treatment by study staff.
Sample collection and analysis procedures
Sample collection and storage. Consenting participants will be provided plastic contain-
ers for collection of a stool sample, to be submitted within 24 hours. Stool will be collected
from households or, if necessary, delivered to a central location, depending on participant
preference. Stool samples will be divided into aliquots for microscopic examination, DNA
extraction, and storage as appropriate. Stool samples intended for DNA extraction and stored
for subsequent analyses will be cryopreserved at -80˚C.
Participants in the longitudinal cohort will have finger prick blood samples taken at the
final round of follow-up to contribute whole blood, stored as dried blood spots on filter paper
for evaluation of antigen detection of infection and measurement of immune response to STH
infection and clearance. Future applications to relevant ethical review committees will be
made for any unspecified analyses.
Participants in the post-MDA coverage surveys who are selected for the coverage validation
sub-study will be provided with plastic containers and asked to provide a urine sample at the
time of the survey. Samples will be cryopreserved at -20˚C for subsequent analyses.
Laboratory procedures. Aliquots of all stool samples will be stored for parasite DNA
extraction and qPCR analysis to detect the presence and intensity of infection with each indi-
vidual species of STH [20]. All sites will ship duplicates of 10% of all study samples to the cen-
tral laboratory facility at Christian Medical College (CMC) in Vellore, India for quality
assurance and control. CMC will in turn ship 10% of samples to Smith College, Massachusetts,
USA for quality assurance and control. A subset of samples positive by qPCR will be stored for
subsequent screening for anthelminthic resistance mutations.
A second aliquot of samples selected for Kato-Katz will be analyzed in duplicate by micros-
copy. These aliquots will be analyzed within 24 hours of collection and within 30 minutes of
sample preparation, to prevent the degradation of hookworm eggs. Two slides will be prepared
and analyzed per specimen. Ten percent of slides will be submitted for quality control checks
to be performed by laboratory supervisors. Laboratory personnel will be blinded to treatment
allocation during assessment.
Urine samples collected for validation during the post-MDA coverage survey will be ana-
lyzed using high performance liquid chromatography (HPLC) for the detection of albendazole
metabolites.
Statistical analysis plan
Primary analyses will be intent-to-treat and conducted separately for each site, unless other-
wise specified. Missing data on individual-level characteristics will be estimated using multiple
imputation.
Primary objectives. The effect of the primary exposure, MDA strategy, on endline infec-
tion with each STH species (Objective 1) will be analyzed using generalized estimating equa-
tions with binomial family and exchangeable correlation matrix. The primary exposure
variable will be randomization arm, while the primary outcome will be individual-level STH
infection status (positive or negative for each STH species by qPCR). Models may be adjusted
for baseline cluster-level STH prevalence and SES, WASH access, age, gender of the
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participant, household size, or other relevant variables as appropriate; both adjusted and unad-
justed estimates will be presented. In the primary analysis, data will be analyzed separately by
site, while a secondary analysis will pool all data and test for effect modification by study site
using an interaction term.
Transmission interruption in a cluster (Objective 2) will be defined as achieving a preva-
lence of each STH species of2% with 95% confidence using a one-sided binomial test, by
qPCR 24 months after the final round of MDA. Measured endline prevalence will be weighted
by age and sex to reflect the underlying cluster population. The effect of the primary exposure
on successful transmission interruption will be calculated by comparing the proportion of
clusters in each arm in which transmission is successfully interrupted using a chi-squared test.
Secondary objectives. The effect of MDA strategy on endline infection with any STH spe-
cies overall among children born during the trial (Objective 3) will be analyzed using general-
ized estimating equations with binomial family and exchangeable correlation matrix, as
detailed above. Models may be adjusted for baseline cluster-level STH prevalence and SES,
WASH access, age, gender of the participant, household size, or other relevant variables as
appropriate.
Secondary analyses. The effect of MDA strategy on treatment coverage a) overall and b)
among SAC and PSAC will be analyzed using self-reported coverage (defined as receiving and
ingesting albendazole during the timeframe of the most recent round of MDA) from post-
MDA coverage surveys in each arm. The effect of randomization arm on self-reported cover-
age will be analyzed using generalized estimating equations with binomial family and
exchangeable correlation matrix and may be adjusted for age, gender, current school atten-
dance, and study year or other relevant variables as appropriate.
Cluster-level correlates of STH transmission interruption (as defined by reaching a cluster
prevalence of each STH2% 24 months after stopping MDA) will be assessed using logistic
regression. Key correlates of breaking the transmission of STH will include baseline prevalence
and species-specific distribution of STH infection, age distribution, population migration lev-
els, treatment coverage and compliance, rates of open defecation and population density.
Sample size estimates
Study areas in each country will have a minimum population of 80,000 people, and clusters
will have a minimum population of 1,650 individuals. The minimum cluster size was selected
to reduce the probability of repeatedly sampling the same individuals at all three cross-sec-
tional time points to<10%, allowing for 10% refusal rate and the exclusion of the longitudinal
monitoring cohort from the eligible population.
Power for primary objectives. For Primary Objective 1, comparing the endline preva-
lence of each STH species at each site, power calculations for a range of scenarios were con-
ducted. The following formula[21]:
c ¼ 1þ ðZ/=2 þ ZbÞ
2 ½p0ð1   p0Þ þ p1ð1   p1Þ½1þ ðm   1Þr
mðp0   p1Þ
2
was used to calculate the prevalence in the control clusters (π0) that would enable detection of
a difference between arms with 80% power, given an endline prevalence in the intervention
clusters (π1) of 2% and a range of assumptions of intracluster correlation coefficient (ρ = 0.003
to ρ = 0.005), number of clusters per arm (c = 15 to c = 20) and number of people sampled per
cluster (m = 500 or m = 1,000), assuming α = 0.05. The detectable alternative π0 ranged from
3% to 3.5% (data not shown).
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Power to detect differences in final prevalence between arms given plausible values for π0,
ranging from 7% to 10%, was then estimated using simulations conducted in R (R Center for
Statistical Computing, Vienna. Austria). Each simulation assumed 1,000 individuals per clus-
ter and a binomial distribution of STH prevalence with a mean of 2% in the intervention clus-
ters and π0 in the control arm, a range of ICC and α = 0.05; 10,000 repetitions were run for
each scenario. Power was98% for all scenarios simulated.
Power for Primary Objective 2, to detect transmission interruption and differences in the
proportion of clusters where transmission is interrupted by arm, was also estimated using sim-
ulation in R. The threshold for transmission interruption was set at 2% prevalence, and a clus-
ter was considered to have interrupted transmission if prevalence could be declared to be
below the threshold with 95% confidence, using a one-sided binomial test. Simulations esti-
mated power to detect a difference in the proportion of clusters in which transmission was
interrupted by arm.
Simulations assumed 20 clusters per arm, 500 or 1,000 individuals per cluster (m), and a
binomial distribution of STH prevalence with a mean of 7% in the targeted arm (π0) and π1 in
the intervention arm, a range of ICC (ρ = 0.003 or ρ = 0.005), and α = 0.05; 10,000 repetitions
were run for each scenario. For a fixed mean endline prevalence of 7% in the targeted arm
(π0), power to detect a difference in the proportion of clusters in which transmission is inter-
rupted by arm varies by number of individuals sampled per cluster, ICC and endline preva-
lence in the intervention arm (π1), as shown in Fig 4.
These power calculations demonstrate that with 20 clusters per arm, evaluating the STH
infection status of 500–1,000 people per cluster at endline would provide >80% power for the
primary objectives in most scenarios. Thus, a target sample size of 500 individuals at baseline
Fig 4. Power to detect a difference in the proportion of clusters achieving transmission interruption (Primary
Objective 2) assuming 7% mean prevalence in the targeted clusters (π0), by mean endline prevalence in the
intervention clusters (π1), intracluster correlation (ICC) and number of people measured per cluster (m),
estimated by simulation.
https://doi.org/10.1371/journal.pntd.0006166.g004
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and post-intervention (6 months post-MDA) and 1,000 individuals at endline (24 months
post-MDA) was chosen per cluster for the cross-sectional prevalence assessments.
Potential risks and challenges
A major risk to the DeWorm3 Project is low treatment coverage and/or adherence, particu-
larly if the same individuals are repeatedly missed [15, 22, 23]. Low coverage could be a result
of failure to access sufficient proportions of the population or suboptimal adherence (i.e. par-
ticipants do not consume the drugs they are given), or be due to high rates of population
migration. Migration could further pose risks to the project due to potential importation of
infection from outside of the study area. Although not applicable to the sites selected for
DeWorm3, a high baseline prevalence of Trichuris infection was recognized as a significant
risk to an MDA-only strategy for transmission interruption during the planning stages of the
study. Owing to the low cure rate of Trichuris with albendazole, transmission interruption
through MDA in such a setting would be particularly challenging and would likely require use
of combination therapy[24, 25]. Reduced cure rates due to resistance mutations are also a con-
cern; STH resistance to benzimidazole anthelminthics is commonly detected in animal sam-
ples and resistance mutations have been documented in parasites infecting humans [26, 27].
The emergence of resistance in the context of expanding MDA to the full population could
pose a risk to the success of transmission interruption, and will be monitored in samples col-
lected during the study. Other potential challenges include political instability, the presence of
transmission hotspots in areas with low coverage, and unprogrammed MDA activities in
either trial arm.
Conclusion
If the DeWorm3 field trials demonstrate that transmission is successfully interrupted at one or
more sites, this will provide evidence of the feasibility of an MDA-based approach to STH
elimination. Secondary analyses will identify cluster-level factors associated with successful
interruption and will provide evidence of the effect of community-wide MDA on prevalence
and infection intensity, reinfection rates and the emergence of benzimidazole resistance. The
DeWorm3 field trials will provide stakeholders with information to evaluate the potential to
switch from a control to an elimination strategy and to optimize future programs and policies
to achieve maximum impact.
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